|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006826,
umls-concept:C0029246,
umls-concept:C0030705,
umls-concept:C0035168,
umls-concept:C0087111,
umls-concept:C0239307,
umls-concept:C0280100,
umls-concept:C0348016,
umls-concept:C0872152,
umls-concept:C0920321,
umls-concept:C1257890,
umls-concept:C1450556,
umls-concept:C2603343,
umls-concept:C2606367
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2004-11-19
|
|
pubmed:abstractText |
Aviscumine is an Escherichia coli-derived recombinant type II ribosome-inactivating protein with potent antitumor activity in vitro and in vivo. It is the recombinant counterpart of natural mistletoe lectin-I. The current study was performed to determine the safety profile, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of the intravenous (i.v.) administration of aviscumine in cancer patients. Translational research included the evaluation of pharmacokinetics and monitoring of plasma cytokine and anti-aviscumine antibody induction after administration of the drug.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:BaronBB,
pubmed-author:BolteOO,
pubmed-author:CamponiAA,
pubmed-author:European Organization for Research and Treatment of Cancer New Drug...,
pubmed-author:FumoleauPP,
pubmed-author:HeroldMM,
pubmed-author:LacombeDD,
pubmed-author:LentzenHH,
pubmed-author:MarreaudSS,
pubmed-author:RiggertSS,
pubmed-author:SchöffskiPP,
pubmed-author:TwelvesCC,
pubmed-author:Wilhelm-OgunbiyiKK,
pubmed-author:ZwierzinaHH
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1816-24
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15550588-Adjuvants, Immunologic,
pubmed-meshheading:15550588-Adult,
pubmed-meshheading:15550588-Aged,
pubmed-meshheading:15550588-Female,
pubmed-meshheading:15550588-Half-Life,
pubmed-meshheading:15550588-Humans,
pubmed-meshheading:15550588-Immune System,
pubmed-meshheading:15550588-Infusions, Intravenous,
pubmed-meshheading:15550588-Male,
pubmed-meshheading:15550588-Maximum Tolerated Dose,
pubmed-meshheading:15550588-Middle Aged,
pubmed-meshheading:15550588-Neoplasms,
pubmed-meshheading:15550588-Plant Preparations,
pubmed-meshheading:15550588-Plant Proteins,
pubmed-meshheading:15550588-Ribosome Inactivating Proteins, Type 2,
pubmed-meshheading:15550588-Toxins, Biological,
pubmed-meshheading:15550588-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
|
|
pubmed:affiliation |
Department of Haematology and Oncology, Hannover Medical School, Hannover, Germany. Patrick.schoffski@uz.kuleuven.ac.be
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase I
|
